895 related articles for article (PubMed ID: 26592919)
1. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
[TBL] [Abstract][Full Text] [Related]
2. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
[TBL] [Abstract][Full Text] [Related]
3. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S59-76. PubMed ID: 11370251
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.
Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B
Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822
[TBL] [Abstract][Full Text] [Related]
5. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
7. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
8. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
11. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
[TBL] [Abstract][Full Text] [Related]
12. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
15. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
17. Case Report: An Atypical Case of Post-Kala-Azar Dermal Leishmaniasis with Ulcers and Verrucous Lesions: Clinical and Therapeutic Implications.
Mathachan SR; Khurana A; Bansal A; Singhai M; Kumari R; Sardana K; Sood V; Khatri P; Singh I
Am J Trop Med Hyg; 2024 Jan; 110(1):40-43. PubMed ID: 38011733
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing post-kala-azar dermal leishmaniasis from leprosy: experience in the Sudan.
el Hassan AM; Hashim FA; Abdullah M; Zijlstra EE; Ghalib HW
Lepr Rev; 1993 Mar; 64(1):53-9. PubMed ID: 8464317
[TBL] [Abstract][Full Text] [Related]
19. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
20. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
